Original Articles
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
https://doi.org/10.4084/MJHID.2026.017

ASSOCİATİON BETWEEN IRON OVERLOAD AND GLUCOSE METABOLİSM İN CHİLDREN AND YOUTH WİTH TRANSFUSİON-DEPENDENT BETA THALASSEMİA: THE ROLE OF CHELATİON THERAPY

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: February 28, 2026
559
Views
308
Downloads
55
HTML

Authors

Deniz Guven
deniz.guven06@hotmail.com
Department of Pediatrics, University of Health and Sciences, Ankara Etlik City Hospital, Ankara, Türkiye, Türkiye.
Dr. İncefidan
1Department of Pediatrics, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Türkiye, , Türkiye.
Dr. Kazanci
Department of Pediatric Hematology and Oncology, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Türkiye, Türkiye.
Dr. Ozlem Kara
Department of Pediatric  Endocrinology, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Türkiye, Türkiye.

Background: Transfusion-dependent thalassemia (TDT) is a transfusion-dependent anemia frequently associated with iron overload, which may disrupt liver function and glucose metabolism.

Objective: This study aimed to evaluate glucose dysregulation and the effects of iron chelation therapy in pediatric TDT patients.

Methodology: This retrospective study included 31 children and adolescents (aged 7–23 years) with TDT who were followed at a tertiary-care pediatric hematology center with available oral glucose tolerance test (OGTT) data. Clinical and laboratory data were analyzed, including oral glucose tolerance test (OGTT), serum ferritin, alanine aminotransferase (ALT), glycated hemoglobin (Hb A1c), C-peptide, homeostatic model assessment for insulin resistance (HOMA-IR), abdominal ultrasonography (USG), and liver and cardiac magnetic resonance imaging (MRI). Diagnosis of diabetes mellitus (DM) and prediabetes was based on American Diabetes Association (ADA) criteria.

Results: OGTT was performed in 28 patients; impaired fasting glucose (IFG) was observed in 10.7%, impaired glucose tolerance (IGT) in 3.6%, and 85.7% had normal glucose regulation. All received consistent oral chelation with film-coated deferasirox. ALT showed significant correlation with age at chelation onset (r=0.49, p=0.00), C-peptide (r=0.45, p=0.02), and age at diagnosis (r=0.56, p=0.001). Duration of chelation correlated with hepatomegaly severity (r=0.61, p=0.00), 30-minute glucose (r=0.39, p=0.03), and insulin levels at 30 (r=0.37, p=0.04) and 90 minutes (r=0.39, p=0.03). No significant association was found between ferritin and OGTT values (p>0.05).

Conclusions: Overt glucose metabolism disorders were uncommon and should be interpreted cautiously. These results highlight the critical role of adherence to chelation and metabolic monitoring to prevent DM in children with TDT.

Key Words: Beta thalassemia major, Iron overload, Oral glucose tolerance test, Diabetes mellitus

 

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
1. Taher A, Vichinsky E, Musallam KM, Cappellini MD, Viprakasit V. Guidelines for the management of non-transfusion dependent thalassaemia (NTDT). In: Weatherall DJ, editor. Thalassaemia International Federation.Nicosia (Cyprus): Thalassaemia International Federation; 2013.
2. Sevimli C, Yilmaz Y, Bayramoglu Z, Comert RG, Gul N, Dursun M, Karakas Z. Pancreatic MR imaging and endocrine complications in patients with beta-thalassemia: a single-center experience. Clin Exp Med.2022;22:95–101. doi:10.1007/s10238-021-00720-9.
3. Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017;2017(1):265–71. doi:10.1182/asheducation-2017.1.265.
4. De Sanctis V, Soliman AT, Elsedfy H, Albu A, Al Jaouni S, Anastasi S, Petrakos G, Kattamis C. Management of adult female thalassemia patients with hypogonadism: review and ICET-A recommendations. Mediterr J Hematol Infect Dis. 2017;9(1):e2017001. doi:10.4084/MJHID.2017.001.
5. Kattamis C, Ladis V, Skafida M, Iacovidou N, Theodoridis C. Different patterns of insulin response during oral glucose tolerance test in transfused young patients with beta-thalassemia. Acta Biomed. 2021;92:e2021265. doi:10.23750/abm.v92iS2.11457.
6. Diab AM, Abdelmotaleb GS, Eid KA, Mostafa ESS, Ahmed ES. Evaluation of glycemic abnormalities in children and adolescents with β-thalassemia major. Egypt Pediatr Assoc Gaz. 2021;69(1):1–7. doi:10.1186/s43054-021-00052-4.
7. El Kholy M, Elsedfy H, Soliman AT, Anastasi S, Raiola G, De Sanctis V. Optimization of the management of endocrine complications of thalassemia. J Pediatr Endocrinol Metab. 2014;27(9-10):801–5. doi:10.1515/jpem-2013-0444.
8. Li MJ, Peng SSF, Lu MY, Chang HH, Yang YL, Jou ST, Lin DTS, Lin KH. Diabetes mellitus in patients with thalassemia major. Pediatr Blood Cancer. 2014;61(1):20–4. doi:10.1002/pbc.24754.
9. De Sanctis V, Soliman AT, Tzoulis P, Daar S, Pozzobon GC, Kattamis C. Isolated hyperglycemia at 1-hour OGTT in β-transfusion dependent thalassemia: 12-year follow-up. Acta Biomed. 2021;92(4):e2021322. doi:10.23750/abm.v92i4.11105.
10. De Sanctis V, Soliman AT, Elsedfy H, Pepe A, Kattamis C, El Kholy M, Daar S. Diabetes and glucose metabolism in thalassemia major: an update. Expert Rev Hematol. 2016;9(4):401–8. doi:10.1586/17474086.2016.1136209.
11. Carsote M, Vasiliu C, Trandafir AI, Albu SE, Dumitrascu MC, Popa A, Dobrican M. Thalassemic endocrine disease: transfusion-dependent thalassemia and endocrine involvement. Diagnostics (Basel). 2022;12(8):1921. doi:10.3390/diagnostics12081921.
12. De Sanctis V, Soliman AT, Tzoulis P, Daar S, Di Maio S, Fiscina B, Kattamis C. Glucose metabolism and insulin response to OGTT in prepubertal patients with transfusion-dependent β-thalassemia. Mediterr J Hematol Infect Dis. 2021;13(1):e2021051. doi:10.4084/MJHID.2021.051.
13. Lala V, Zubair M, Minter DA. Liver function tests. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
14. Gomber S, Dabas A, Bagmar S, Madhu SV. Glucose homeostasis and effect of chelation on β-cell function in children with β-thalassemia major. J Pediatr Hematol Oncol. 2018;40(1):56–9. doi:10.1097/MPH.0000000000000982. doi:10.5222/buchd.2020.35556
15. Malik SE, Kanwal S, Javed J, Hidayat W, Ghaffar T, Aamir AH. Endocrine disorders in transfusion-dependent thalassemia patients at a tertiary care hospital. Pak J Med Sci. 2023;39(3):726–31. doi: https://doi.org/10.12669/pjms.39.3.6837
16. Fianza PI, Rahmawati A, Widihastha SH, Afifah S, Ghozali M, Indrajaya A, Setiawan CH, Rachmadi D, Djuwantono T. Iron overload in transfusion-dependent Indonesian thalassemic patients. Anemia.2021;2021:5581831. doi:10.1155/2021/5581831.
17. Bhat KG, Periasamy PK. Effect of long-term transfusion therapy on glycometabolic status and pancreatic beta-cell function in patients with beta-thalassemia major. J Family Med Prim Care. 2014;3(2):119–23. doi:10.4103/2249-4863.137621.
18. Güler-Kazancı E, Kızılsoy ÖF, Aksoy GR, Güven D, Kaya E. A case of beta thalassemia major: multidisciplinary treatment approach. Pediatr Acad Case Rep. 2025;4(1):20–4. doi: 10.61107/pacr.2024.164
19. Habeb A, Deeb A, Hamza RT, Iughetti L, Jalaludin MY, Muze KC, Oyenusi EE, Rodda C, Singh P, Skordis N, Suliman AT, Vogiatzi MG, Zolaly M, Charmandari E. International consensus guideline on the diagnosis and management of endocrine complications of β and α thalassemia in children and adolescents. Horm Res Paediatr. 2025;1–24. doi:10.1159/000546904.
20. Habbash F, Al-Bati W, Al-Hashim H, Aldossari M, Alali A, Alalyani K, Al-Mubarak A, Al-Otaibi R. Endocrine complications and compliance with chelation therapy in beta-thalassemia major in Eastern Province of Saudi Arabia. J Blood Med. 2022;13:763–74. doi:10.2147/JBM.S387812.
21. Ghergherehchi R, Habibzadeh A. Insulin resistance and β-cell function in patients with β-thalassemia major. Hemoglobin. 2015;39(2):69–73. doi:10.3109/03630269.2014.1001526.
22. Meloni A, Pistoia L, Putti MC, Longo F, Corigliano E, Ricchi P, Rossi V, Casini T, Righi R, Renne S, Peritore G, Barbuto L, Cademartiri F. Pancreatic iron in pediatric transfusion-dependent beta-thalassemia patients: a longitudinal MRI study. Pediatr Blood Cancer. 2024;71(5):e30923. doi:10.1002/pbc.30923.
23. Zhang Z, Hou B, Du G, Sun P, Guan W, Lin Q, Han B, Yu W. Association of hepatic/pancreatic iron overload evaluated by quantitative T2* MRI with bone mineral density and trabecular bone score. BMC Endocr Disord.2023;23(1):2. doi:10.1186/s12902-022-01262-6.
24. Pan J, Liao Y, Huang Q, Ji G, Dai R, Lin D. Associations between serum ferritin, iron, and liver transaminases in adolescents. Nutr Hosp. 2023;40(3):949–59. doi:10.20960/nh.04341.
25. De Sanctis V, Soliman AT, Daar S, Tzoulis P, Di Maio S, Fiscina B, Kattamis C. Could plasma glucose (PG) increment (PG%) expand the clinical weight of OGTT? Preliminary findings in TDT patients with normal glucose tolerance. Mediterr J Hematol Infect Dis. 2025;17(1):e2025050. doi:10.4084/MJHID.2025.050.
26. Venou TM, Kyriakidis F, Barmpageorgopoulou F, Theodoridou S, Vyzantiadis A, Klonizakis P, Gavriilaki E, Vlachaki E. Risk factors for impaired glucose metabolism in transfusion-dependent patients with β-thalassemia: a single-center retrospective observational study. Hematol Rep. 2025;17(1):6. doi:10.3390/hematolrep17010006.
27. Karunaratna AM, Ranasingha JG, Mudiyanse RM. Endocrine complications of beta-thalassemia major patients — cross-sectional analysis of risk factors. Int J Blood Transfus Immunohematol.2020;10:Z02AK2020AK. doi:10.5348/100051Z02AK2020AK.
28. Al-Zamili SLM. Endocrinopathies’ prevalence in beta-thalassemia major patients. Indones J Health Sci Med.2025;2(2):266. doi:10.21070/ijhsm.v2i2.266.
29. Salunkhe M, Sajjan S, Sajjan A, Patil MM. Endocrine manifestations in children and adolescents with thalassemia major: prospective cohort study. Int J Child Health Nutr. 2025;14(3):4. doi:10.6000/1929-4247.2025.14.03.4.
30. Mahmoud AA, El-Hawy MA, Alla ET, Salem AH. HbA1c or fructosamine on evaluating glucose intolerance in children with beta-thalassemia. Pediatr Res. 2024;96(3):415–22. doi:10.1038/s41390-024-03146-y.
Dr. Ozlem Kara, Department of Pediatric  Endocrinology, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Türkiye

Department of Pediatric  Endocrinology, Bursa Yüksek İhtisas Training and Research Hospital, Bursa, Türkiye

How to Cite



“ASSOCİATİON BETWEEN IRON OVERLOAD AND GLUCOSE METABOLİSM İN CHİLDREN AND YOUTH WİTH TRANSFUSİON-DEPENDENT BETA THALASSEMİA: THE ROLE OF CHELATİON THERAPY” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1). doi:10.4084/MJHID.2026.017.
Copyright (c) 2026 Deniz Guven, Dr. İncefidan, Dr. Kazanci, Dr. Ozlem Kara Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.